Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific share repurchase transaction executed on June 14, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 1,000,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,295 pence per share; lowest price paid was 1,285 pence per share.
- Treasury Shares Held: 499,174,284 shares (representing 8.84% of total issued share capital and 9.69% of total voting rights).
- Shares in Issue: 5,150,371,827 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 1,000,000 repurchased shares. This transaction increased the proportion of Treasury shares held by the Company relative to the total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,150,371,827) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.69%).
- Note that the repurchased shares were cancelled, permanently reducing the share count.